Adverse reactions of second-line tyrosine kinase inhibitors in advanced hepatocellular carcinoma treatment: a descriptive analysis from WHO-VigiAccess

Key Points

• Severe gastrointestinal toxicity risks are significantly higher with cabozantinib than regorafenib, indicating a need for caution.
• The analysis shows that male patients aged 45-64 are particularly vulnerable to toxic effects when using cabozantinib.
• Routine liver-function monitoring and early dose modifications are crucial for safe treatment initiation of cabozantinib.
• Data emphasizes the potential for personalized treatment strategies following first-line therapy failure, aiming for better outcomes.